Google DeepMind spinout Isomorphic Labs has raised $2.1bn (£1.6bn) in Series B funding.
Founded in 2021, Isomorphic Labs uses AI to transform and accelerate the drug discovery process. This latest round of investment will scale the companyʼs evolution from pioneering novel AI models to applying them at scale.
The Series B round is led by Thrive Capital and includes participation from existing backers Alphabet and GV, plus new investors MGX, Temasek and CapitalG. The UK’s sovereign AI fund, launched last month, also contributed to the round.
The new capital will be used for the continued development and deployment of Isomorphic Labsʼ AI drug design engine IsoDDE, accelerating and expanding its pipeline of therapeutic programs towards the clinic. The investment will also be used to support the company’s hiring targets.
“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,ˮ says Max Jaderberg, president of Isomorphic Labs.
“Our drug design engine works and it’s giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.ˮ
The Series B builds on Isomorphic Labs’ £462.3m funding round announced in April 2025.
